177 related articles for article (PubMed ID: 32950694)
21. Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma.
Badar T; Johnson BD; Hamadani M
Bone Marrow Transplant; 2021 Mar; 56(3):683-685. PubMed ID: 32782349
[No Abstract] [Full Text] [Related]
22. Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
Zhao WL; Wu DP; Hu Y
N Engl J Med; 2023 Sep; 389(12):1152-1153. PubMed ID: 37733322
[No Abstract] [Full Text] [Related]
23. Axicabtagene Ciloleucel in Large B-Cell Lymphoma. Reply.
Westin JR; To C; Locke FL
N Engl J Med; 2023 Sep; 389(12):1152-1153. PubMed ID: 37733323
[No Abstract] [Full Text] [Related]
24. [New European approvals: Tisagenlecleucel and Axicabtagene ciloleucel CAR-T cells - Follicular lymphoma after at least two and three prior lines of therapy].
Cordeil S; Bachy E
Bull Cancer; 2022 Nov; 109(11):1106-1108. PubMed ID: 36088178
[No Abstract] [Full Text] [Related]
25. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.
Roth JA; Sullivan SD; Lin VW; Bansal A; Purdum AG; Navale L; Cheng P; Ramsey SD
J Med Econ; 2018 Dec; 21(12):1238-1245. PubMed ID: 30260711
[TBL] [Abstract][Full Text] [Related]
26. Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy.
Byrne M; Oluwole OO; Savani B; Majhail NS; Hill BT; Locke FL
Biol Blood Marrow Transplant; 2019 Nov; 25(11):e344-e351. PubMed ID: 31279751
[TBL] [Abstract][Full Text] [Related]
27. What CAR Will Win the CD19 Race?
Quintás-Cardama A
Mol Cancer Ther; 2019 Mar; 18(3):498-506. PubMed ID: 30824581
[TBL] [Abstract][Full Text] [Related]
28. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
Abbasi A; Peeke S; Shah N; Mustafa J; Khatun F; Lombardo A; Abreu M; Elkind R; Fehn K; de Castro A; Wang Y; Derman O; Nelson R; Uehlinger J; Gritsman K; Sica RA; Kornblum N; Mantzaris I; Shastri A; Janakiram M; Goldfinger M; Verma A; Braunschweig I; Bachier-Rodriguez L
J Hematol Oncol; 2020 Jan; 13(1):1. PubMed ID: 31900191
[TBL] [Abstract][Full Text] [Related]
29. Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement.
Novo M; Ruff MW; Skrabek PJ; Lin Y
Mayo Clin Proc; 2019 Nov; 94(11):2361-2364. PubMed ID: 31685159
[No Abstract] [Full Text] [Related]
30. FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma.
Bouchkouj N; Zimmerman M; Kasamon YL; Wang C; Dai T; Xu Z; Wang X; Theoret M; Purohit-Sheth T; George B
Oncologist; 2022 Jul; 27(7):587-594. PubMed ID: 35403693
[TBL] [Abstract][Full Text] [Related]
31. Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis.
Mian A; Wei W; Winter AM; Khouri J; Jagadeesh D; Anwer F; Gerds AT; Dean RM; Sobecks R; Pohlman B; Hamilton BK; Majhail NS; Hill BT
Leuk Lymphoma; 2021 Jun; 62(6):1344-1352. PubMed ID: 33375873
[TBL] [Abstract][Full Text] [Related]
32. Axicabtagene ciloleucel for CD19+ plasmablastic lymphoma.
Raychaudhuri R; Qualtieri J; Garfall AL
Am J Hematol; 2020 Jan; 95(1):E28-E30. PubMed ID: 31725923
[No Abstract] [Full Text] [Related]
33. C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel.
Melody M; Rahman ZA; Saunders H; Diaz PL; Gannon N; Rosenthal A; Ayala E; Tun HW; Murthy H; Roy V; Foran J; Castro JE; Guru P; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):141-146. PubMed ID: 33069694
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Neelapu SS; Jacobson CA; Oluwole OO; Munoz J; Deol A; Miklos DB; Bartlett NL; Braunschweig I; Jiang Y; Kim JJ; Zheng L; Rossi JM; Locke FL
Blood; 2020 Jun; 135(23):2106-2109. PubMed ID: 32181801
[No Abstract] [Full Text] [Related]
35. CAR T-cell product performance in haematological malignancies before and after marketing authorisation.
Elsallab M; Levine BL; Wayne AS; Abou-El-Enein M
Lancet Oncol; 2020 Feb; 21(2):e104-e116. PubMed ID: 32007196
[TBL] [Abstract][Full Text] [Related]
36. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response.
Jallouk AP; Gouni S; Westin J; Feng L; Mistry H; Steiner RE; James J; Noorani M; Horowitz S; Puebla-Osorio N; Fayad LE; Iyer SP; Hawkins M; Flowers CR; Ahmed S; Nastoupil LJ; Kebriaei P; Shpall EJ; Neelapu SS; Nieto Y; Strati P
Haematologica; 2023 Apr; 108(4):1163-1167. PubMed ID: 36384251
[No Abstract] [Full Text] [Related]
37. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
38. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
Sesques P; Ferrant E; Safar V; Wallet F; Tordo J; Dhomps A; Karlin L; Brisou G; Vercasson M; Hospital-Gustem C; Schwiertz V; Ranchon F; Rioufol C; Choquet M; Sujobert P; Ghergus D; Bouafia F; Golfier C; Lequeu H; Lazareth A; Novelli S; Devic P; Traverse Glehen A; Viel S; Venet F; Mialou V; Hequet O; Chauchet A; Arkam Y; Nicolas-Virelizier E; Peyrade F; Cavalieri D; Ader F; Ghesquières H; Salles G; Bachy E
Am J Hematol; 2020 Nov; 95(11):1324-1333. PubMed ID: 32744738
[TBL] [Abstract][Full Text] [Related]
39. Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel.
Hoogland AI; Jayani RV; Collier A; Irizarry-Arroyo N; Rodriguez Y; Jain MD; Booth-Jones M; Hyland KA; James BW; Barata A; Bachmeier CA; Chavez JC; Khimani F; Krivenko GS; Lazaryan A; Liu HD; Nishihori T; Pinilla-Ibarz J; Shah BD; Abidi M; Locke FL; Jim HSL
Cancer Med; 2021 Mar; 10(6):1936-1943. PubMed ID: 33641257
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.
Spiegel JY; Dahiya S; Jain MD; Tamaresis J; Nastoupil LJ; Jacobs MT; Ghobadi A; Lin Y; Lunning M; Lekakis L; Reagan P; Oluwole O; McGuirk J; Deol A; Goy A; Vu K; Andreadis C; Munoz J; Bennani NN; Vose JM; Dorritie KA; Neelapu SS; Locke FL; Rapoport AP; Hill BT; Miklos DB
Blood; 2021 Apr; 137(13):1832-1835. PubMed ID: 33156925
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
